Significant lower VVH7-like immunoreactivity serum level in diabetic patients: Evidence for independence from metabolic control and three key enzymes in hemorphin metabolism, cathepsin D, ACE and DPP-IV

Peptides

Volumn 30, Issue 2, 2009, Pages 256-261

  Feron, D ^a   Begu Le Corroller, A ^b   Piot, J M ^a   Frelicot, C ^c   Vialettes, B ^b   Fruitier Arnaudin, I ^a  

^a CNRS   (France)

^b TIMONE HOSPITAL   (France)

^c UNIVERSITÉ DE LA ROCHELLE   (France)

Author keywords

diabetes; Serum angiotensin converting enzyme; Serum cathepsin D; Serum dipeptidyl peptidase IV; VVH7 i.r

Indexed keywords

CATHEPSIN D; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL PEPTIDASE IV; HEMORPHIN 7; NEUROPEPTIDE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MONITORING; CORRELATION ANALYSIS; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE;

ADULT; AGED; ANTIGENS, CD26; BLOOD PRESSURE; CATHEPSIN D; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBINS; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PEPTIDYL-DIPEPTIDASE A;

EID: 58249097452     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2008.11.004     Document Type: Article

References (34)

1. Association A.D. Diagnosis and classification of diabetes mellitus. Diabetes Care 31 (2008) 55-60
2. Cejka J., Zelezna B., Velek J., Zicha J., and Kunes J. LVV-hemorphin-7 lowers blood pressure in spontaneously hypertensive rats: radiotelemetry study. Physiological Research 53 (2004) 603-607
3. Cohen M., Fruitier-Arnaudin I., Garreau-Balandier I., and Piot J.M. Quantification of hemorphin-7 peptides by enzyme linked immunosorbent assay with secondary antibody. Analytica Chimica Acta 461 (2002) 229-233
4. Cohen M., Fruitier-Arnaudin I., and Piot J.M. Hemorphins: substrates and/or inhibitors of dipeptidyl peptidase IV-hemorphins N-terminus sequence influence on the interaction between hemorphins and DPPIV. Biochimie 86 (2004) 31-37
5. Cohen M., Fruitier-Arnaudin I., Sauvan R., Birnbaum D., and Piot J.M. Serum levels of hemorphin-7 peptides in patients with breast cancer. Clinica Chimica Acta 337 (2003) 59-67
6. Cushman D.W., and Cheung H.S. Spectrophotometric assay and properties of the angiotensin-converting enzyme of rabbit lung. Biochemical pharmacology 20 (1971) 1637-1648
7. Dost A., Klinkert C., Kapellen T., Lemmer A., Naeke A., Grabert M., et al. Arterial hypertension determined by ambulatory blood pressure profiles: contribution to microalbuminuria risk in a multicenter investigation in 2,105 children and adolescents with type 1 diabetes. Diabetes care 31 (2008) 720-725
8. Fruitier-Arnaudin I., Cohen M., Bordenave S., Sannier F., and Piot J.-M. Comparative effects of angiotensin IV and two hemorphins on angiotensin-converting enzyme activity. Peptides 23 (2002) 1465-1470
9. Fruitier-Arnaudin I., Cohen M., Nervi S., Bordenave S., Sannier F., and Piot J.M. Reduced level of opiod H7 peptides in serum of diabetic patients. Diabetes Care 26 (2003) 2480
10. Garreau I. VV-hemorphin-7 and LVV-hemorphin-7 released during in vitro peptic hemoglobin hydrolysis are morphinomimetic peptides. Neuropeptides 28 (1995) 243-250
11. Garreau I., Chansel D., Vandermeersch S., Fruitier I., Piot J.-M., and Ardaillou R. Hemorphins inhibit angiotensin IV binding and interact with aminopeptidase N. Peptides 19 (1998) 1339-1348
12. Glamsta E.L., Morkrid L., Lantz I., and Nyberg F. Concomitant increase in blood plasma levels of immunoreactive hemorphin-7 and beta-endorphin following long distance running. Regulatory peptides 49 (1993) 9-18
13. Hamilton T.A., Handa R.K., Harding J.W., and Wright J.W. A role for the angiotensin IV/AT4 system in mediating natriuresis in the rat. Peptides 22 (2001) 935-944
14. Hino M., Fuyamada H., and Hayakawa T. X prolyl dipeptidyl aminopeptidase activity, with X proline p nitroanilides as substrates, in normal and pathological human sera. Clinical Chemistry 22 (1976) 1256-1261
15. Ianzer D., Konno K., Xavier C.H., Stocklin R., Santos R.A., de Camargo A.C., et al. Hemorphin and hemorphin-like peptides isolated from dog pancreas and sheep brain are able to potentiate bradykinin activity in vivo. Peptides 27 (2006) 2957-2966
16. Jarmolowska B., Bielikowicz K., Iwan M., Sidor K., Kostyra E., and Kaczmarski M. Serum activity of dipeptidyl peptidase IV (DPPIV; EC 3,4. 14. 5) in breast-fed infants with symptoms of allergy. Peptides 28 (2007) 678-682
17. John H., John S., and Forssmann W.G. Kinetic studies on aminopeptidase M-mediated degradation of human hemorphin LVV-H7 and its N-terminally truncated products. Journal of Peptide Science (2008)
18. Lantz I., Glamsta E.L., Talback L., and Nyberg F. Hemorphins derived from hemoglobin have an inhibitory action on angiotensin converting enzyme activity. FEBS letters 287 (1991) 39-41
19. Lee J., Albiston A.L., Allen A.M., Mendelsohn F.A., Ping S.E., Barrett G.L., et al. Effect of I.C.V. injection of AT4 receptor ligands, NLE1-angiotensin IV and LVV-hemorphin 7, on spatial learning in rats. Neuroscience 124 (2004) 341-349
20. Liu J., Ma L., Yang J., Ren A., Sun Z., Yan G., et al. Increased serum cathepsin S in patients with atherosclerosis and diabetes. Atherosclerosis 186 (2006) 411-419
21. Llorente L., De La Fuente H., Richaud-Patin Y., Alvarado-De La Barrera C., Diaz-Borjón A., López-Ponce A., et al. Innate immune response mechanisms in non-insulin dependent diabetes mellitus patients assessed by flow cytoenzymology. Immunology Letters 74 (2000) 239-244
22. Lurbe E., Redon J., Kesani A., Pascual J.M., Tacons J., Alvarez V., et al. Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes. The New England journal of medicine 347 (2002) 797-805
23. McKillop A.M., Duffy N.A., Lindsay J.R., O'Harte F.P.M., Bell P.M., and Flatt P.R. Decreased dipeptidyl peptidase-IV activity and glucagon-like peptide-1(7-36)amide degradation in type 2 diabetic subjects. Diabetes Research and Clinical Practice 79 (2008) 79-85
24. Moeller I., Lew R.A., Mendelsohn F.A., Smith A.I., Brennan M.E., Tetaz T.J., et al. The globin fragment LVV-hemorphin-7 is an endogenous ligand for the AT4 receptor in the brain. Journal of neurochemistry 68 (1997) 2530-2537
25. Ryskjaer J., Deacon C., Carr R., Krarup T., Madsbad S., Holst J., et al. Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake. European journal of endocrinology 155 (2006) 797-803
26. Sanderson K., Nyberg F., and Khalil Z. Modulation of peripheral inflammation by locally administered hemorphin-7. Inflammation research 47 (1998) 49-55
27. Silberring J., and Nyberg F. Rapid analysis of endogenous LVV-hemorphin-7 in cerebrospinal fluid by size-exclusion chromatography and electrospray ionization mass spectrometry. Journal of chromatography A 777 (1997) 41-45
28. Smith R., Turk V., and Cathepsin D. Rapid isolation by affinity chromatography on haemoglobin agarose resin. European Journal of Biochemistry 48 (1974) 245-254
29. Taleb S., Cancello R., Poitou C., Rouault C., Sellam P., Levy P., et al. Weight loss reduces adipose tissue cathepsin S and its circulating levels in morbidly obese women. Journal of Clinical Endocrinology and Metabolism 91 (2006) 1042-1047
30. Turner R., Holman R., Stratton I., Cull C., Frighi V., Manley S., et al. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. British Medical Journal 317 (1998) 703-713
31. Yang R., Smolders I., De Bundel D., Fouyn R., Halberg M., Demaegdt H., et al. Brain and peripheral angiotensin II type 1 receptors mediate renal vasoconstrictor and blood pressure responses to angiotensin IV in the rat. Journal of Hypertension 26 (2008) 998-1007
32. Ye S., Chai S.Y., Lew R.A., and Albiston A.L. Insulin-regulated aminopeptidase: analysis of peptide substrate and inhibitor binding to the catalytic domain. Biological chemistry 388 (2007) 399-403
33. Zhao Q., Garreau I., Sannier F., and Piot J.M. Opioid peptides derived from hemoglobin: hemorphins. Biopolymers 43 (1997) 75-98
34. Zhao Q., Garreau I., Sannier F., and Piot J.M. Opioid peptides derived from hemoglobin: hemorphins. Biopolymers-Peptide Science Section 43 (1997) 75-98